If you have questions, please call us for more information about clinical trials or use our online form.
- Cancer clinical trials: 414-805-8900
- Noncancer clinical trials: 414-955-8555
Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.
Displaying 131 - 140 of 279
A Multicenter, Phase 1, Open-Label, Dose-Escalation and Expansion Study of AZD0486, a Bispecific Antibody Targeting CD19 in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Objective
A Study of TNB-486 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Protocol No
TENEOBIO-TENEOTWO-TNB486-001
A Phase 1 Study of NTX-301, an Oral DNMT1 Inhibitor, in Patients with MDS and AML
Objective
A phase 1 study of NTX-301 in patients with MDS and AML
Protocol No
UAB-19113-NTX-301
Categories
Ablation with Confirmation of Colorectal Liver Metastases (ACCLAIM) Prospective Trial for Microwave Ablation as a Local Cure
Objective
Ablation With Confirmation of Colorectal Liver Metastases (ACCLAIM)
Protocol No
SIO-2021-01-ACCLAIM
Categories
A Phase 1, Open-Label, Multicenter, Dose Escalation Study of SGR-1505 as Monotherapy in Patients with Mature B-Cell Malignancies
Objective
A Phase 1 Study if SGR-1505 in Patients with B-Cell Malignancies
Protocol No
SCHRODINGER-SGR-1505-101
Categories
Randomized Phase II/III Trial of Adjuvant Radiation Therapy with Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Objective
The purpose of this part of this study is to compare the effects, good and/or bad, of the standard treatment (radiation therapy and cisplatin) with one of the experimental treatments chosen from the first part of the study (either radiation therapy and docetaxel or radiation therapy, cetuximab, and docetaxel) to find out which is better.
Protocol No
RTOG-1216
Categories
A Randomized Phase II Study of INC280 (Capmatinib) plus Osimertinib with or without Ramucirumab in Participants with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)
Objective
Comparing drugs for advanced non-small cell lung cancer with EGFR and MET gene changes
Protocol No
SWOG-S1900G
Categories
A Randomized, Open-Label Study of HLX10 Plus Chemotherapy (Carboplatin-Etoposide) in Comparison with Atezolizumab Plus Chemotherapy in Previously Untreated US Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Objective
A randomized study to compare Atezolizumab plus Chemotherapy vs HLX10 plus Chemo in ES-SCLC
Protocol No
SHB-HLX10-005-SCLC301-E
Categories
A First-in-Human, Phase 1/2, Dose Escalation Study of BOXR1030 T Cells in Subjects with Advanced GPC3-Positive Solid Tumors
Objective
BOXR1030 T Cells in Advanced GPC3-Positive Solid Tumors
Protocol No
SOTIO-BOXR1030
Categories
PROmoting CLinicAl TrIal EngageMent for Pancreatic Cancer App Study (PROCLAIM Study)
Objective
Promoting CT Engagement for Pancreatic Cancer With App (PROCLAIM)
Protocol No
UNC-LCCC2234-PROCLAIM
Categories
A First-in-Human, Multicenter, Phase 1, Open-Label Study of XTX301 in Patients with Advanced Solid Tumors
Objective
A First-in-Human, Open-Label Study of XTX301 in Patients with Advanced Solid Tumors
Protocol No
XILIO-XTX301-01-02-001
Categories
Cancer,
Gynecologic Cancers,
Esophagus,
Thoracic Cancers,
Colorectal,
Early Phase/Multiple Disease Site Cancers,
Kidney,
Other Skin,
Pancreas/Liver,
Other Urologic,
Prostate and Urologic Cancers,
Stomach,
Skin Cancers,
Head and Neck Cancers,
Esophagus,
Gastrointestinal Cancers,
Sarcoma,
Breast Cancers